Theranos ends the year on thin ice financially, CNBC's Meg Tirrell reports.
Randal Kirk, Intrexon CEO chairman & CEO, discusses the biotech company's advances in genetic engineering.
The “Fast Money” weigh in on the biotech sector, as the iShares Nasdaq Biotechnology ETF IBB continues to surge.
Marathon Pharmaceuticals delays the launch of their $89,000 muscular dystrophy drug amid drug pricing concerns. CNBC's Meg Tirrell reports.
Congress targets Marathon Pharmaceuticals over the company's high drug prices. CNBC's Meg Tirrell reports.
A judge rules Regeneron's cholesterol drug can stay on the market amid the company's ongoing patent case with Amgen. CNBC's Meg Tirrell reports.
Jeremy Levin, Ovid Therapeutics CEO, former Teva Pharmaceuticals CEO, speaks to CNBC's Meg Tirrell about how President Trump's immigration plans may impact the biotech industry.
Earnings are out for Gilead. CNBC's Meg Tirrell reports the details.
The "Fast Money" traders run down their list of trades to make as U.S. markets rallied Friday.
The "Fast Money" traders digest Amazon's and Amgen's earnings reported after the bell on Thursday.
CNBC's Meg Tirrell reports on after-hours action for Amgen. The "Fast Money" traders weigh in.
Earnings are out for Amgen. CNBC's Meg Tirrell reports the details.
CNBC's Meg Tirrell reports on President Trump's meeting with big pharmaceutical CEOs, and how it is impacting the biotech sector. The "Fast Money" traders weigh in.
Joel Marcus, Alexandria Real Estate equities, talks about the immigration ban, and the benefits of tax repatriation from the biotech industry.
In an official statement, Mylan denies it illegally tried to prevent competition. CNBC's Meg Tirrell reports.
Dr. Peter Bach, Memorial Sloan Kettering Center for Health Policy & Outcomes director, discusses why the government should "nationalize" Gilead to help reduce the price of hepatitis C drugs.
The Fast Money traders discuss whether the pharmaceutical company will be acquired.
"Fast Money" trader David Seaburg pitches to the desk why to buy Eli Lilly.
The new CMS classification means the device is eligible for Medicaid and Medicare coverage.
The “Fast Money” traders discusses whether Donald Trump is a risk to his own market rally, as he continues to target different sectors with criticism.